Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: A prospective, randomized, placebo-controlled trial

Objective Gastric acid inhibition is beneficial in the management of peptic ulcer bleeding (PUB). The aim of this double-blind study was to test whether somatostatin (SST) increases intragastric pH in PUB as compared with pantoprazole (PAN) and placebo (PLA). Material and methods Eligible patients w...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of gastroenterology 2005-05, Vol.40 (5), p.515-522
Main Authors: Avgerinos, Alec, Sgouros, Spiros, Viazis, Nikos, Vlachogiannakos, John, Papaxoinis, Kostis, Bergele, Christina, Sklavos, Pantelis, Raptis, Sotiris A.
Format: Article
Language:English
Subjects:
2-Pyridinylmethylsulfinylbenzimidazoles
Anti-Ulcer Agents - therapeutic use
Benzimidazoles - therapeutic use
Biological and medical sciences
Double-Blind Method
Female
Gastric Acid - secretion
Gastric acid inhibition
Gastric Acidity Determination
Gastroenterology. Liver. Pancreas. Abdomen
Hormones - therapeutic use
Humans
Hydrogen-Ion Concentration
Male
Medical sciences
Middle Aged
Omeprazole - analogs & derivatives
Omeprazole - therapeutic use
Other diseases. Semiology
pantoprazole
peptic ulcer bleeding
Peptic Ulcer Hemorrhage - drug therapy
Prospective Studies
Proton Pump Inhibitors
somatostatin
Somatostatin - therapeutic use
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Sulfoxides - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Gastric acid inhibition is beneficial in the management of peptic ulcer bleeding (PUB). The aim of this double-blind study was to test whether somatostatin (SST) increases intragastric pH in PUB as compared with pantoprazole (PAN) and placebo (PLA). Material and methods Eligible patients were randomized to receive SST (500 μg/h+250 μg bolus), or PAN (8 mg/h+80 mg bolus) or PLA (normal saline) i.v., for 24 h. All patients underwent gastric pH monitoring during the infusion of the trial drugs. Results The three groups (SST, n=14; PAN, n=14; PLA, n=15) were comparable for age, gender, aetiology of PUB and laboratory data at admission. Mean (±SE) baseline pH levels in the fundus increased during the administration of the trial drugs (SST: 1.94±0.18 to 6.13±0.37, p
ISSN:0036-5521
1502-7708
DOI:10.1080/00365520510015458